Laman UtamaNZYMB • SWX
add
Novozymes A/S
Tutup sebelumnya
CHFÂ 44.68
Julat tahun
CHFÂ 44.68 - CHFÂ 44.68
Permodalan pasaran
185.99B DKK
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
CPH
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (EUR) | Mac 2025info | Perubahan T/T |
|---|---|---|
Hasil | 1.08B | 26.26% |
Perbelanjaan pengendalian | 318.60J | 26.73% |
Pendapatan bersih | 186.00J | 458.56% |
Margin untung bersih | 17.26 | 342.56% |
Pendapatan bagi setiap syer | 3.14 | — |
EBITDA | 412.80J | 31.76% |
Kadar cukai berkesan | 23.99% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (EUR) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 249.50J | 66.67% |
Jumlah aset | 15.06B | — |
Jumlah liabiliti | 3.83B | — |
Jumlah ekuiti | 11.23B | — |
Syer tertunggak | 466.19J | — |
Harga kepada buku | 1.85 | — |
Pulangan pada aset | 4.56% | — |
Pulangan pada modal | 5.32% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (EUR) | Mac 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 186.00J | 458.56% |
Tunai daripada operasi | 106.40J | -39.72% |
Tunai daripada pelaburan | -38.30J | -25.57% |
Tunai daripada pembiayaan | -102.10J | -13.57% |
Perubahan bersih dalam tunai | -30.50J | -148.34% |
Aliran tunai bebas | 63.55J | — |
Perihal
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. Wikipedia
CEO
Diasaskan
2000
Tapak web
Pekerja
10,582
